Product Description
Floxuridine (FUDR) is a pyrimidine analogue used as an antineoplastic agent, usually as a continuous hepatic arterial infusion to treat hepatic metastases from colon cancer. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Floxuridine)
Mechanisms of Action: DNA Synthesis Inhibitor, TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral, Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Italy | United States
Approved Indications: None
Known Adverse Events: None
Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05865925 |
LY01616/CT-CHN-101 | P2 |
Enrolling by invitation |
Oncology Solid Tumor Unspecified |
2024-08-31 |
7% |
2024-11-27 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/07/2025 |
News Article |
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma |
|
03/12/2025 |
News Article |
City of Hope's Phase 1 Clinical Trial Data Is Part of the Society of Surgical Oncology Annual Meeting's Press Program |
|
08/05/2024 |
News Article |
Sirtex Medical Launches SIR-Spheres® FLEXdose SELECT Delivery Program to Enable More Selective Y-90 Treatment Plans |
|
10/26/2022 |
News Article |
NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022 |